NCT00897104

MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)

A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Compare the Efficacy and Safety of MK0462 5 mg p.o. and Sumatriptan 50 mg p.o. for the Acute Treatment of Migraine

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 933 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A study to compare rizatriptan (MK0462) 5 mg by mouth (p.o.) and sumatriptan 50 mg p.o. for the acute treatment of a migraine attack.

Conditions

• Migraine Headache

Interventions

Type	Name	Description
DRUG	rizatriptan benzoate (MK0462)	single dose 5 mg rizatriptan p.o.
DRUG	Comparator: sumatriptan	single dose 50 mg sumatriptan p.o.
DRUG	Comparator: Placebo	Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally

Timeline

• Start date: 1995-08-01
• Primary completion: 1996-05-01
• Completion: 1996-09-01
• First posted: 2009-05-12
• Last updated: 2022-02-03
• Results posted: 2010-07-23